Locked content Pharmena files prospectus to move to WSE main market

Listed on the small-cap, alternative NewConnect market, biotechnology company Pharmena, filed the prospectus with the Financial Supervision Authority KNF to transfer its shares to the WSE main market, the company said in a market filing. In H1, the company had PLN 0.5 million net profit, compared wi...

Locked content Pharmena mulls switch to WSE main market

Listed on the small-cap, alternative NewConnect market, biotechnology company Pharmena, plans to transfer its shares to the main WSE market by the end of this year, the company said in a market filing. In H1, the company had PLN 0.5 million net profit, compared with PLN 1.5 million loss last year. R...

Locked content Pharmena creates unit in Germany

NewConnect-listed biotech company Pharmena established a special purpose company Menavitin in Germany. Menavitin will sell dietary supplements containing 1-MNA on the German, Austrian and Swiss markets, Pharmena said. It owns 92.5 percent shares in Menavitin. The remaining 7.5 percent belong to Frit...

Locked content Pharmena revenue drops

Listed on the alternative, small-cap market, pharmaceutical, Pharmena, had PLN 1.74 million net profit in 2016, a drop from PLN 2.7 million in 2015. Revenue from sales amounted to PLN 17 million (PLN 18.4 million in 2015), the company said in its financial report. “The decrease stems, from low...

Locked content Polish health care company may enter London or NY stock exchange

A Polish health care company, Pharmena is considering moving its shares from the NewConnect alternative market to another main exchange, not necessarily the WSE. The firm is willing to debut on the London Stock Exchange or the New York Stock Exchange. “The decision will be made … at the ...